Xenetic Biosciences, Inc. entered into a definitive Share Exchange Agreement on September 14, 2026, to acquire Santersus AG in an all-stock transaction expected to close in the fourth quarter of 2026. Upon closing, Santersus shareholders will own approximately 85% of the combined company, which will be renamed Santersus Bio, Inc., and trade on Nasdaq under the symbol “SNTS.” The merger combines Xenetic’s DNase technology with Santersus’ NucleoCapture® platform to target neutrophil extracellular traps (NETs) across critical care, autoimmune disease, transplantation, and oncology. The combined entity will hold four first-in-class clinical programs, including pivotal-stage initiatives in sepsis and systemic lupus erythematosus that have received FDA Breakthrough Device Designation. Xenetic stockholders are expected to retain approximately 15% ownership post-transaction.

Xenetic Biosciences reported financial results for the quarter ended June 30, 2026. Royalty revenue increased approximately 12% to $0.7 million, while research and development expenses decreased 16% to $0.6 million. General and administrative expenses rose 64% to $1.1 million due to legal costs associated with a strategic review process. The company reported a net loss of approximately $0.9 million compared to $0.7 million in the prior year period. Cash and cash equivalents stood at $6.5 million as of June 30, 2026. Highlights include positive preclinical data presented at ASCO regarding DNase I enhancing CAR T-cell therapy outcomes and regulatory approval for an investigator-initiated study by partner PeriNess Ltd. Xenetic Biosciences is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers.